Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Survey of UK histopathology consultants' attitudes towards academic and molecular pathology.

Brockmoeller S, Young C, Lee J, Arends MJ, Wilkins BS, Thomas GJ, Oien KA, Jones L, Hunter KD.

J Clin Pathol. 2019 Jun;72(6):399-405. doi: 10.1136/jclinpath-2018-205568. Epub 2019 Mar 25.

2.

Barriers to the release of human tissue for clinical trials research in the UK: a national survey of cellular pathology laboratories on behalf of the National Cancer Research Institute's Cellular Molecular Pathology (CM-Path) initiative.

Macklin PS, Hall A, Lee J, Hair J, Speirs V, Thomas GJ, Oien KA, Verrill C.

J Clin Pathol. 2019 Jan;72(1):52-57. doi: 10.1136/jclinpath-2018-205476. Epub 2018 Oct 1.

PMID:
30275096
3.

Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme.

Lindsay CR, Shaw EC, Blackhall F, Blyth KG, Brenton JD, Chaturvedi A, Clarke N, Dick C, Evans TRJ, Hall G, Hanby AM, Harrison DJ, Johnston SRD, Mason MD, Morton D, Newton-Bishop J, Nicholson AG, Oien KA, Popat S, Rassl D, Sharpe R, Taniere P, Walker I, Wallace WA, West NP, Butler R, Gonzalez de Castro D, Griffiths M, Johnson PWM.

ESMO Open. 2018 Sep 5;3(6):e000408. doi: 10.1136/esmoopen-2018-000408. eCollection 2018.

4.

Digital pathology access and usage in the UK: results from a national survey on behalf of the National Cancer Research Institute's CM-Path initiative.

Williams BJ, Lee J, Oien KA, Treanor D.

J Clin Pathol. 2018 May;71(5):463-466. doi: 10.1136/jclinpath-2017-204808. Epub 2018 Jan 9.

5.

Morphomolecular pathology: setting the framework for a new generation of pathologists.

Jones JL, Oien KA, Lee JL, Salto-Tellez M.

Br J Cancer. 2017 Nov 21;117(11):1581-1582. doi: 10.1038/bjc.2017.340. Epub 2017 Nov 9. No abstract available.

6.

Time for change: a new training programme for morpho-molecular pathologists?

Moore DA, Young CA, Morris HT, Oien KA, Lee JL, Jones JL, Salto-Tellez M.

J Clin Pathol. 2018 Apr;71(4):285-290. doi: 10.1136/jclinpath-2017-204821. Epub 2017 Nov 7. Review.

7.

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma.

Wong NACS, Adamczyk LA, Evans S, Cullen J, Oniscu A, Oien KA.

Histopathology. 2017 Jul;71(1):34-41. doi: 10.1111/his.13194. Epub 2017 Apr 11.

PMID:
28226180
8.

A Glasgow Tipple-transjugular intrahepatic portosystemic shunt insertion prior to Whipple resection.

Jabbar SA, Jamieson NB, Morris AJ, Oien KA, Duthie F, McKay CJ, Carter CR, Dickson EJ.

J Surg Case Rep. 2016 May 13;2016(5). pii: rjw089. doi: 10.1093/jscr/rjw089.

9.

Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer Agreement.

Ali A, Bell S, Bilsland A, Slavin J, Lynch V, Elgoweini M, Derakhshan MH, Jamieson NB, Chang D, Brown V, Denley S, Orange C, McKay C, Carter R, Oien KA, Duthie FR.

Appl Immunohistochem Mol Morphol. 2017 Oct;25(9):599-608. doi: 10.1097/PAI.0000000000000357.

PMID:
27093449
10.

Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.

Gingras MC, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N, Fisher WE; Australian Pancreatic Cancer Genome Initiative, Pilarsky C, Grützmann R, Overman MJ, Jamieson NB, Van Buren G 2nd, Drummond J, Walker K, Hampton OA, Xi L, Muzny DM, Doddapaneni H, Lee SL, Bellair M, Hu J, Han Y, Dinh HH, Dahdouli M, Samra JS, Bailey P, Waddell N, Pearson JV, Harliwong I, Wang H, Aust D, Oien KA, Hruban RH, Hodges SE, McElhany A, Saengboonmee C, Duthie FR, Grimmond SM, Biankin AV, Wheeler DA, Gibbs RA.

Cell Rep. 2016 Feb 2;14(4):907-919. doi: 10.1016/j.celrep.2015.12.005. Epub 2016 Jan 21.

11.

Prevalent low-grade dysplasia: the strongest predictor of malignant progression in Barrett's columnar-lined oesophagus.

Moyes LH, Oien KA, Foulis AK, Fullarton GM, Going JJ.

Gut. 2016 Feb;65(2):360-1. doi: 10.1136/gutjnl-2015-309978. Epub 2015 Jun 17. No abstract available.

12.

Drug- not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano- and micro-particles: size does not matter.

Venkatpurwar VP, Rhodes S, Oien KA, Elliott MA, Tekwe CD, Jørgensen HG, Kumar MN.

Toxicology. 2015 Apr 1;330:9-18. doi: 10.1016/j.tox.2015.01.017. Epub 2015 Jan 28.

13.

Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel.

Ali A, Brown V, Denley S, Jamieson NB, Morton JP, Nixon C, Graham JS, Sansom OJ, Carter CR, McKay CJ, Duthie FR, Oien KA.

BMC Clin Pathol. 2014 Jul 23;14:35. doi: 10.1186/1472-6890-14-35. eCollection 2014.

14.

Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961-2010.

Brewster DH, Lang J, Bhatti LA, Thomson CS, Oien KA.

Cancer Epidemiol. 2014 Jun;38(3):227-34. doi: 10.1016/j.canep.2014.03.010. Epub 2014 Apr 13.

PMID:
24726751
15.

Targeting mTOR dependency in pancreatic cancer.

Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ; Australian Pancreatic Cancer Genome Initiative (APGI), Oien KA, McKay CJ, Carter CR, Gillen G, Champion S, Pimlott SL, Anderson KI, Evans TR, Grimmond SM, Biankin AV, Sansom OJ, Morton JP.

Gut. 2014 Sep;63(9):1481-9. doi: 10.1136/gutjnl-2013-306202. Epub 2014 Apr 9.

16.

Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater.

Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, Pinese M, Humphris JL, Jones MD, Toon C, Nagrial AM, Chantrill LA, Chin VT, Pinho AV, Rooman I, Cowley MJ, Wu J, Mead RS, Colvin EK, Samra JS, Corbo V, Bassi C, Falconi M, Lawlor RT, Crippa S, Sperandio N, Bersani S, Dickson EJ, Mohamed MA, Oien KA, Foulis AK, Musgrove EA, Sutherland RL, Kench JG, Carter CR, Gill AJ, Scarpa A, McKay CJ, Biankin AV.

J Clin Oncol. 2013 Apr 1;31(10):1348-56. doi: 10.1200/JCO.2012.46.8868. Epub 2013 Feb 25.

PMID:
23439753
17.

Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, Edwards J, McKay CJ.

J Gastrointest Surg. 2013 May;17(5):887-98. doi: 10.1007/s11605-013-2168-7. Epub 2013 Feb 23.

PMID:
23435739
18.
19.

The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma.

Jamieson NB, Mohamed M, Oien KA, Foulis AK, Dickson EJ, Imrie CW, Carter CR, McKay CJ, McMillan DC.

Ann Surg Oncol. 2012 Oct;19(11):3581-90. doi: 10.1245/s10434-012-2370-y. Epub 2012 May 4.

PMID:
22555345
20.

Improvement of parenteral nutrition-associated cholestasis in an adult using fish oil-based parenteral nutrition.

Moyes LH, Hamid R, Clutton J, Oien KA, McKee RF, Forrest EH.

Frontline Gastroenterol. 2012 Apr;3(2):94-97. doi: 10.1136/flgastro-2011-100056. Epub 2012 Mar 13.

21.

MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.

Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA.

Clin Cancer Res. 2012 Jan 15;18(2):534-45. doi: 10.1158/1078-0432.CCR-11-0679. Epub 2011 Nov 23.

22.

Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.

Steele CW, Oien KA, McKay CJ, Jamieson NB.

Pancreas. 2011 Nov;40(8):1165-71. doi: 10.1097/MPA.0b013e3182218ffb. Review.

PMID:
22001830
23.

Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.

Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, Enders GH, Zhang R, Sansom OJ, Adams PD.

Mol Cell. 2011 Apr 8;42(1):36-49. doi: 10.1016/j.molcel.2011.02.020.

24.

Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.

Jamieson NB, Carter CR, McKay CJ, Oien KA.

Clin Cancer Res. 2011 May 15;17(10):3316-31. doi: 10.1158/1078-0432.CCR-10-3284. Epub 2011 Mar 28. Review.

25.

Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Jamieson NB, Foulis AK, Oien KA, Dickson EJ, Imrie CW, Carter R, McKay CJ.

J Gastrointest Surg. 2011 Mar;15(3):512-24. doi: 10.1007/s11605-010-1395-4. Epub 2010 Nov 30.

PMID:
21116727
26.
27.

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ.

J Clin Invest. 2010 Aug;120(8):2842-57. doi: 10.1172/JCI36125. Epub 2010 Jul 1.

28.

Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma.

Jamieson NB, Foulis AK, Oien KA, Going JJ, Glen P, Dickson EJ, Imrie CW, McKay CJ, Carter R.

Ann Surg. 2010 Jun;251(6):1003-10. doi: 10.1097/SLA.0b013e3181d77369.

PMID:
20485150
29.

LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.

Morton JP, Jamieson NB, Karim SA, Athineos D, Ridgway RA, Nixon C, McKay CJ, Carter R, Brunton VG, Frame MC, Ashworth A, Oien KA, Evans TR, Sansom OJ.

Gastroenterology. 2010 Aug;139(2):586-97, 597.e1-6. doi: 10.1053/j.gastro.2010.04.055. Epub 2010 May 6.

30.

Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.

Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, Frame MC, Evans TR, Sansom OJ, Brunton VG.

Gastroenterology. 2010 Jul;139(1):292-303. doi: 10.1053/j.gastro.2010.03.034. Epub 2010 Mar 17.

PMID:
20303350
31.

Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series.

Morris JM, Oien KA, McMahon M, Forrest EH, Morris J, Stanley AJ, Campbell S.

Eur J Gastroenterol Hepatol. 2010 Aug;22(8):1001-5. doi: 10.1097/MEG.0b013e3283360021.

PMID:
20075739
32.

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.

Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR, Sansom OJ.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):246-51. doi: 10.1073/pnas.0908428107. Epub 2009 Dec 14.

33.

The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers.

Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC.

J Gastrointest Surg. 2009 Nov;13(11):2011-8; discussion 2018-9. doi: 10.1007/s11605-009-1034-0. Epub 2009 Sep 19.

PMID:
19768511
34.

Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms.

Lafferty-Whyte K, Cairney CJ, Jamieson NB, Oien KA, Keith WN.

Biochim Biophys Acta. 2009 Apr;1792(4):341-52. doi: 10.1016/j.bbadis.2009.02.003. Epub 2009 Feb 12. Review.

35.

Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer.

Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC.

Eur J Cancer. 2009 Aug;45(12):2138-45. doi: 10.1016/j.ejca.2009.04.011. Epub 2009 May 4.

PMID:
19409772
36.

Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer.

Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC.

Ann Surg. 2009 May;249(5):788-93. doi: 10.1097/SLA.0b013e3181a3e738.

PMID:
19387324
37.

Pathologic evaluation of unknown primary cancer.

Oien KA.

Semin Oncol. 2009 Feb;36(1):8-37. doi: 10.1053/j.seminoncol.2008.10.009. Review.

PMID:
19179185
38.

Raising the profile of cancer of unknown primary.

Oien KA, Evans TR.

J Clin Oncol. 2008 Sep 20;26(27):4373-5. doi: 10.1200/JCO.2008.17.6156. No abstract available.

PMID:
18802148
39.

Loss of MSH2 protein expression is a risk factor in early stage cervical cancer.

Nijhuis ER, Nijman HW, Oien KA, Bell A, ten Hoor KA, Reesink-Peters N, Boezen HM, Hollema H, van der Zee AG.

J Clin Pathol. 2007 Jul;60(7):824-30.

40.

Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo.

Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V, Jamieson TJ, Guerra C, Ashton GH, Barbacid M, Clarke AR.

Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7. Epub 2006 Sep 7.

41.

Identification of blottin: a novel gastric trefoil factor family-2 binding protein.

Otto WR, Patel K, McKinnell I, Evans MD, Lee CY, Frith D, Hanrahan S, Blight K, Blin N, Kayademir T, Poulsom R, Jeffery R, Hunt T, Wright NA, McGregor F, Oien KA.

Proteomics. 2006 Aug;6(15):4235-45.

PMID:
16888721
42.

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.

de Graeff P, Hall J, Crijns AP, de Bock GH, Paul J, Oien KA, ten Hoor KA, de Jong S, Hollema H, Bartlett JM, Brown R, van der Zee AG.

Br J Cancer. 2006 Sep 4;95(5):627-33. Epub 2006 Aug 1.

43.

Bleeding gastric varices and antiphospholipid syndrome.

Gaya DR, Oien KA, Stanley AJ, Morris AJ.

Nat Clin Pract Gastroenterol Hepatol. 2005 Mar;2(3):156-9; quiz 1 p following 159.

PMID:
16265157
44.

Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection.

Forrest EH, Thorburn D, Spence E, Oien KA, Inglis G, Smith CA, McCruden EA, Fox R, Mills PR.

J Viral Hepat. 2005 Sep;12(5):519-24.

PMID:
16108768
45.

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.

Westra JL, Hollema H, Schaapveld M, Platteel I, Oien KA, Keith WN, Mauritz R, Peters GJ, Buys CH, Hofstra RM, Plukker JT.

Ann Oncol. 2005 Oct;16(10):1646-53. Epub 2005 Jul 12.

PMID:
16012177
46.

Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.

Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA.

Clin Cancer Res. 2005 May 15;11(10):3766-72.

47.

Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.

Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J, Brown R.

Gynecol Oncol. 2005 Jun;97(3):898-903.

PMID:
15894365
48.

Hunting the primary: novel strategies for defining the origin of tumours.

Dennis JL, Oien KA.

J Pathol. 2005 Jan;205(2):236-47. Review.

PMID:
15641019
49.

Duodenal vasculitis.

Gaya DR, Oien KA, Fox J.

Gastrointest Endosc. 2004 Oct;60(4):602-3. No abstract available.

PMID:
15472689
50.

Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation.

Oien KA, McGregor F, Butler S, Ferrier RK, Downie I, Bryce S, Burns S, Keith WN.

J Pathol. 2004 Jul;203(3):789-97.

PMID:
15221938

Supplemental Content

Support Center